5-(3-fluoro-4-hydroxyphenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one | 946505-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(3-fluoro-4-hydroxyphenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one
• 英文别名: 2-anilino-5-(3-fluoro-4-hydroxyphenyl)-3-methylpyrimidin-4-one
• CAS: 946505-30-2
• 化学式: C₁₇H₁₄FN₃O₂
• 分子量: 311.315
• InChiKey: SZSRRQJEEWUMSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3-fluoro-4-hydroxyphenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one 、 4-chloro-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine 在 4-二甲氨基吡啶 氮气 、 溴苯 、 methanol-dichloromethane 作用下， 以 溴苯 为溶剂， 反应 72.0h， 以The desired product (0.013 g, 76%) was obtained as a yellow solid的产率得到5-(3-fluoro-4-(3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one
  参考文献：
  名称：

  Heterobicyclic pyrazole compounds and methods of use

  摘要：

  公式Ia和Ib的化合物和其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药物可接受的盐，可用于抑制受体酪氨酸激酶并用于治疗由此介导的疾病。揭示了使用公式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药物可接受的盐的方法，用于哺乳动物细胞中的体外、体内和原位诊断、预防或治疗这种疾病或相关病理条件。

  公开号：

  US07723330B2
• 作为产物：
  描述：

  2-anilino-3-methyl-3H-pyrimidin-4-one 在 四(三苯基膦)钯 溴 、 sodium carbonate 、 三氟乙酸 、 lithium chloride 作用下， 以 1,4-二氧六环 、 甲醇 、 氯仿 、 水 为溶剂， 反应 4.33h， 生成 5-(3-fluoro-4-hydroxyphenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one
  参考文献：
  名称：

  WO2007/146824

  摘要：

  公开号：

文献信息

• Heterobicyclic pyrazole compounds and methods of use
  申请人：Blake F. James

  公开号：US20070238726A1

  公开（公告）日：2007-10-11

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。公开了使用化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• Heterobicyclic thiophene compounds and methods of use
  申请人：Blake F. James

  公开号：US20070197537A1

  公开（公告）日：2007-08-23

  Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物及其药用盐可用于抑制受体酪氨酸激酶，并用于治疗由此介导的疾病。公开了使用公式I的化合物及其药用盐的方法，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理情况。
• QUINOLINE COMPOUNDS AND METHODS OF USE
  申请人：Gaudino John

  公开号：US20110053931A1

  公开（公告）日：2011-03-03

  Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、盐和药学上可接受的前药，用于抑制受体酪氨酸激酶并治疗由此介导的过度增殖性疾病。本文揭示了使用式（I）的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Design, Synthesis, and Biological Evaluation of Potent c-Met Inhibitors
  作者：Noel D. D’Angelo、Steven F. Bellon、Shon K. Booker、Yuan Cheng、Angela Coxon、Celia Dominguez、Ingrid Fellows、Douglas Hoffman、Randall Hungate、Paula Kaplan-Lefko、Matthew R. Lee、Chun Li、Longbin Liu、Elizabeth Rainbeau、Paul J. Reider、Karen Rex、Aaron Siegmund、Yaxiong Sun、Andrew S. Tasker、Ning Xi、Shimin Xu、Yajing Yang、Yihong Zhang、Teresa L. Burgess、Isabelle Dussault、Tae-Seong Kim

  DOI：10.1021/jm8006189

  日期：2008.9.25

  c-Met is a receptor tyrosine kinase that plays a key role in several cellular processes but has also been found to be overexpressed and mutated in different human cancers. Consequently, targeting this enzyme has become an area of intense research in drug discovery. Our studies began with the design and synthesis of novel pyrimidone 7, which was found to be a potent c-Met inhibitor. Subsequent SAR studies identified 22 as a more potent analog, whereas an X-ray crystal structure of 7 bound to c-Met revealed an unexpected binding conformation. This latter finding led to the development of a new series that featured compounds that were more potent both in vitro and in vivo than 22 and also exhibited different binding conformations to c-Met. Novel c-Met inhibitors have been designed, developed, and found to be potent in vitro and in vivo.
• HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER
  申请人：Array Biopharma, Inc.

  公开号：EP1989211A2

  公开（公告）日：2008-11-12